Prescription drug prices are at unprecedented levels. A growing number of patients cannot afford the life-saving treatments they need. Despite a widespread outcry from the public to address high prescription drug prices, it has been difficult to generate bipartisan movement on the issue.
Henry Waxman led the charge in balancing drug innovation with price competition, starting with creating the generic drug market with the Hatch-Waxman Act. Since then, a new landscape with sky high prices has developed. To set the stage for Congress to find bipartisan solutions to address high prescription drug prices, the Waxman team crafted a comprehensive report on the problems and drivers of high drug prices as well as broad range of potential policy options to address each problem. This work was done with support and in collaboration with the Commonwealth Fund and Laura and John Arnold Foundation in partnership with the Johns Hopkins Bloomberg School of Public Health.